{"organizations": [], "uuid": "34faddc0c92c97c9cb6130cfdbe9d68a26f0ad3a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-eli-lilly-announces-positive-top-l/brief-eli-lilly-announces-positive-top-line-phase-3-results-for-taltz-idUSFWN1Q30Y0", "country": "US", "domain_rank": 408, "title": "Eli Lilly Announces Positive Top-Line Phase 3 Results For Taltz", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.532, "site_type": "news", "published": "2018-02-13T20:04:00.000+02:00", "replies_count": 0, "uuid": "34faddc0c92c97c9cb6130cfdbe9d68a26f0ad3a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-eli-lilly-announces-positive-top-l/brief-eli-lilly-announces-positive-top-line-phase-3-results-for-taltz-idUSFWN1Q30Y0", "ord_in_thread": 0, "title": "Eli Lilly Announces Positive Top-Line Phase 3 Results For Taltz", "locations": [], "entities": {"persons": [{"name": "lilly", "sentiment": "negative"}, {"name": "taltz", "sentiment": "none"}], "locations": [], "organizations": [{"name": "eli lilly and co", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eli lilly announces positive top-line phase", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Eli Lilly And Co:\n* LILLY ANNOUNCES POSITIVE TOP-LINE PHASE 3 RESULTS FOR TALTZ® (IXEKIZUMAB) IN ANKYLOSING SPONDYLITIS (RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS)\n* ELI LILLY AND CO - TALTZ(®) (IXEKIZUMAB) MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN COAST-V\n* ELI LILLY AND CO - PLANS TO SUBMIT DETAILED DATA FROM COAST-V FOR DISCLOSURE AT SCIENTIFIC MEETINGS AND IN PEER-REVIEWED JOURNALS LATER THIS YEAR\n* ELI LILLY AND CO - PLANS TO SUBMIT FOR REGULATORY APPROVALS PENDING ADDITIONAL DATA FROM ONGOING TALTZ DEVELOPMENT PROGRAM LATER THIS YEAR\n* ELI LILLY AND CO - ‍TALTZ DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT IN SIGNS AND SYMPTOMS OF AS, WHEN COMPARED TO PLACEBO​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T20:04:00.000+02:00", "crawled": "2018-02-14T12:44:34.026+02:00", "highlightTitle": ""}